Findings

What do systematic reviews say?

748 questions · 782 findings · 58 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 164 · 21%GRADE not reported 26 · 3.3%Very low 151 · 19.3%Low 222 · 28.4%Moderate 158 · 20.2%High 61 · 7.8%

Edaravone plus corticosteroids vs corticosteroids

Corticosteroid requirements · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: bevacizumab vs placebo

Reduction in post‐gadolinium enhancement · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…

1 finding from 1 review

Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Low

Summary of findings: bevacizumab vs placebo

Reduction in neurological/clinical symptoms/severity · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…

1 finding from 1 review

Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

Summary of findings: bevacizumab vs placebo

Severe adverse events · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…

1 finding from 1 review

Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Low

Summary of findings: bevacizumab vs placebo

Quality of life · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: bevacizumab vs placebo

Corticosteroid requirements · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Edaravone plus corticosteroids vs corticosteroids

Reduction in oedema (T2 hyperintensity) · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…

Edaravone plus corticosteroids showed no clear difference in reduction in oedema (T2 hyperintensity) compared with corticosteroids (low certainty).

1 finding from 1 review

Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
MD 3.03
1 study · 137 participants
Low

Edaravone plus corticosteroids vs corticosteroids

Reduction in post‐gadolinium enhancement · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…

Edaravone plus corticosteroids showed no clear difference in reduction in post‐gadolinium enhancement compared with corticosteroids (low certainty).

1 finding from 1 review

Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
MD 0.47
1 study · 137 participants
Low

Edaravone plus corticosteroids vs corticosteroids

Improvement in LENT/SOMA · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…

Edaravone plus corticosteroids may leads to higher improvement in LENT/SOMA compared with corticosteroids (low certainty).

1 finding from 1 review

Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
OR 2.51
1 study · 137 participants
Low

Summary of findings: Aminosalicylates vs placebo

Mean GI symptom scores (IBDQ‐B) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Aminosalicylates vs placebo

Acute and late GI toxicity (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

Summary of findings: Aminosalicylates probably leads to higher acute and late GI toxicity (grade 2+) compared with placebo (moderate certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 1.02 [1.22, 1.45]
2 studies · 143 participants
Moderate

Summary of findings: Aminosalicylates vs placebo

Diarrhoea (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Aminosalicylates vs placebo

QoL · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sucralfate vs placebo

Mean GI symptom scores · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sucralfate vs placebo

Acute and late GI toxicity (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

Summary of findings: Sucralfate showed no clear difference in acute and late GI toxicity (grade 2+) [acute = during RT; late = 6… compared with placebo (moderate certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 1.07 [0.83, 1.39]
1 study · 335 participants
Moderate

Sucralfate vs placebo

Diarrhoea (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

Summary of findings: Sucralfate may leads to lower diarrhoea (grade 2+) [during RT] compared with placebo (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.81
4 studies · 284 participants
Low

Sucralfate vs placebo

QoL · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention diet vs usual on‐treatment diet

Elemental diet · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention diet vs usual on‐treatment diet

Mean GI symptom scores (IBDQ‐B) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Low

Intervention diet vs usual on‐treatment diet

Acute and late GI toxicity (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found